Reis IB - Search Results

1

OncoTherad^® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway.

Alonso JCC, de Souza BR, Reis IB, de Arruda Camargo GC, de Oliveira G, de Barros Frazão Salmazo MI, Gonçalves JM, de Castro Roston JR, Caria PHF, da Silva Santos A, de Freitas LLL, Billis A, Durán N, Fávaro WJ. Alonso JCC, et al. Among authors: reis ib. Int J Mol Sci. 2023 Dec 15;24(24):17535. doi: 10.3390/ijms242417535. Int J Mol Sci. 2023. PMID: 38139364 Free PMC article. Clinical Trial.

2

Evaluation of the tissue repair process and immunomodulatory action of Platelet-Rich Plasma (PRP) in the treatment of abdominal stretch marks.

de Castro Roston JR, Reis IB, Luzo ÂCM, Roston MO, Durán N, Fávaro WJ. de Castro Roston JR, et al. Among authors: reis ib. Tissue Cell. 2023 Aug;83:102132. doi: 10.1016/j.tice.2023.102132. Epub 2023 Jun 10. Tissue Cell. 2023. PMID: 37331321

3

New synthetic nano-immunotherapy (OncoTherad®) for non-muscle invasive bladder cancer: Its synthesis, characterization and anticancer property.

Fávaro WJ, Alonso JCC, de Souza BR, Reis IB, Gonçalves JM, Deckmann AC, Oliveira G, Dias QC, Durán N. Fávaro WJ, et al. Among authors: reis ib. Tissue Cell. 2023 Feb;80:101988. doi: 10.1016/j.tice.2022.101988. Epub 2022 Dec 5. Tissue Cell. 2023. PMID: 36521234

4

The Role of By-Products of Fruit and Vegetable Processing for the Dietary Treatment of Cardiovascular Risk Factors: A Narrative Review.

Tavares IRG, Pinheiro VDS, de Castro PMLA, Reis IB, de Oliveira GV, Alvares TS. Tavares IRG, et al. Among authors: reis ib. Antioxidants (Basel). 2022 Nov 1;11(11):2170. doi: 10.3390/antiox11112170. Antioxidants (Basel). 2022. PMID: 36358542 Free PMC article. Review.

5

OncoTherad^® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer.

Reis IB, Tibo LHS, de Souza BR, Durán N, Fávaro WJ. Reis IB, et al. J Cancer Res Clin Oncol. 2023 Jul;149(8):5025-5036. doi: 10.1007/s00432-022-04449-5. Epub 2022 Nov 2. J Cancer Res Clin Oncol. 2023. PMID: 36322290

6

OncoTherad® (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway.

Reis IB, Tibo LHS, Socca EAR, de Souza BR, Durán N, Fávaro WJ. Reis IB, et al. Tissue Cell. 2022 Jun;76:101762. doi: 10.1016/j.tice.2022.101762. Epub 2022 Feb 22. Tissue Cell. 2022. PMID: 35245856

7

Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model.

Fávaro WJ, Socca EAR, Böckelmann PK, Reis IB, Garcia PV, Durán N. Fávaro WJ, et al. Among authors: reis ib. Med Oncol. 2022 Jan 4;39(2):24. doi: 10.1007/s12032-021-01612-9. Med Oncol. 2022. PMID: 34982270

8

Influence of Human Eating Habits on Antimicrobial Resistance Phenomenon: Aspects of Clinical Resistome of Gut Microbiota in Omnivores, Ovolactovegetarians, and Strict Vegetarians.

da Silva SF, Reis IB, Monteiro MG, Dias VC, Machado ABF, da Silva VL, Diniz CG. da Silva SF, et al. Among authors: reis ib. Antibiotics (Basel). 2021 Mar 9;10(3):276. doi: 10.3390/antibiotics10030276. Antibiotics (Basel). 2021. PMID: 33803337 Free PMC article.

9

P-mapa, a promisor immunomodulator against tumor cells of colonic tissues: An investigation of the action mechanism over the TLR4 signaling pathway.

Socca EAR, Reis SK, Genaro SC, Leite SK, Reis IB, Bockëlmann PK, Durán N, Fávaro WJ. Socca EAR, et al. Among authors: reis ib. Life Sci. 2020 Feb 1;242:117185. doi: 10.1016/j.lfs.2019.117185. Epub 2019 Dec 18. Life Sci. 2020. PMID: 31862453 Free article.

10

Photothermia and Activated Drug Release of Natural Cell Membrane Coated Plasmonic Gold Nanorods and β-Lapachone.

Marangoni VS, Cancino Bernardi J, Reis IB, Fávaro WJ, Zucolotto V. Marangoni VS, et al. Among authors: reis ib. ACS Appl Bio Mater. 2019 Feb 18;2(2):728-736. doi: 10.1021/acsabm.8b00603. Epub 2019 Feb 1. ACS Appl Bio Mater. 2019. PMID: 35016277

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11 results

Search Page